Axsome Therapeutics (AXSM) Stock Price, News & Analysis

Company Overview

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Key Stats

• Today's Range: $84.93 to $90.31
• 50-Day Range: $84.61 to $100.49
• 52-Week Range: $64.11 to $105.00
• Volume: 1.16 million shs
• Average Volume: 623,040 shs
• Market Capitalization: $4.23 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $127.07
• Consensus Rating: Buy

Axsome Therapeutics Stock Analysis - MarketRank™

Axsome Therapeutics scored higher than 95% of companies evaluated by MarketBeat, and ranked 68th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.5 / 5
• Analyst Rating: Buy

Consensus Rating

Axsome Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Axsome Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Axsome Therapeutics are expected to grow in the coming year, from ($4.60) to ($1.32) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Axsome Therapeutics is -13.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Axsome Therapeutics is -13.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Axsome Therapeutics has a P/B Ratio of 21.61. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

13.45% of the outstanding shares of Axsome Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Axsome Therapeutics has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Axsome Therapeutics has recently decreased by 7.91%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Axsome Therapeutics does not currently pay a dividend.

Dividend Growth

Axsome Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.5 / 5
• Environmental Score: -1.03

Percentage of Shares Shorted

13.45% of the outstanding shares of Axsome Therapeutics have been sold short.

Short Interest Ratio / Days to Cover

Axsome Therapeutics has a short interest ratio ("days to cover") of 13.4, which indicates bearish sentiment.

Change versus previous month

Short interest in Axsome Therapeutics has recently decreased by 7.91%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.47

News Sentiment

Axsome Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.65 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 25 news articles for Axsome Therapeutics this week, compared to 8 articles on an average week.

Search Interest

33 people have searched for AXSM on MarketBeat in the last 30 days. This is an increase of 313% compared to the previous 30 days.

MarketBeat Follows

Only 4 people have added Axsome Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -43% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Axsome Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

22.40% of the stock of Axsome Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

81.49% of the stock of Axsome Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

AXSM Stock Analysis - Frequently Asked Questions

How have AXSM shares performed this year?

Axsome Therapeutics' stock was trading at $84.61 on January 1st, 2025. Since then, AXSM stock has increased by 3.2% and is now trading at $87.32.
View the best growth stocks for 2025 here.

How were Axsome Therapeutics' earnings last quarter?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) posted its quarterly earnings data on Tuesday, November, 12th. The company reported ($1.34) earnings per share for the quarter, topping the consensus estimate of ($1.38) by $0.04. The firm had revenue of $104.76 million for the quarter, compared to analysts' expectations of $98.71 million. Axsome Therapeutics had a negative trailing twelve-month return on equity of 158.36% and a negative net margin of 91.87%.

When did Axsome Therapeutics IPO?

Axsome Therapeutics (AXSM) raised $52 million in an initial public offering (IPO) on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

How do I buy shares of Axsome Therapeutics?

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Axsome Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Axsome Therapeutics investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Marinus Pharmaceuticals (MRNS).

Company Calendar

• Last Earnings: 11/12/2024
• Today: 1/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AXSM
• CUSIP: N/A
• CIK: 1579428
• Web: axsome.com
• Phone: (212) 332-3241
• Fax: 212-320-0245
• Employees: 589
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $127.07
• High Stock Price Target: $180.00
• Low Stock Price Target: $105.00
• Potential Upside/Downside: +43.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 14 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.53)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-239,240,000.00
• Net Margins: -91.87%
• Pretax Margin: -91.97%
• Return on Equity: -158.36%
• Return on Assets: -37.46%

Debt

• Debt-to-Equity Ratio: 1.97
• Current Ratio: 2.44
• Quick Ratio: 2.37

Sales & Book Value

• Annual Sales: $338.46 million
• Price / Sales: 12.70
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.04 per share
• Price / Book: 21.96

Miscellaneous

• Outstanding Shares: 48,462,000
• Free Float: 37,607,000
• Market Cap: $4.30 billion
• Optionable: Optionable
• Beta: 1.18